Latest filing published 18 May 2023 for Akebia Therapeutics, Inc., €62k.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
David A. Spellman: trading record in brief
David A. Spellman, listed as finance chief, appears in our data through filings on Akebia Therapeutics, Inc. shares, published by SEC (Form 4). The record holds 12 filings, for trades running from 26 February 2021 to 16 May 2023.
On the market, this insider has only sold: 7 sales, €92k in total. The rest of the record consists of 5 share grants. Since January 2023: no purchases and 4 sales on the market.
The newest entry dates from 18 May 2023: an open-market sale of €62k, in Akebia Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to David A. Spellman
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 63,567 shares@ US$1.06871.1% of flowCommon StockSEC:0001562180-23-004253:0
- 6,400 shares@ US$0.87756.0% of flowCommon StockSEC:0001562180-23-002197:0
- 7,539 shares@ US$0.81326.6% of flowCommon StockSEC:0001562180-23-002038:0
- 196,200 shares0Common StockSEC:0001562180-23-000831:0
- 200,000 shares0Common StockSEC:0001562180-22-005001:0
- 7,400 shares@ US$2.154816.2% of flowCommon StockSEC:0001562180-22-002160:0
6 of 6 declarations
